Skip to main content

Sound Advice: February 21, 2024

800-000-0000

That’s 800-000-0000

Again, 800-000-0000

That’s the typical closing for the hard sell commercials that are increasingly polluting media airwaves.  These are the commercials for products or services you rarely need or most definitely should avoid.

A substantial number are on behalf of groups of attorneys who would have you believe that you and many others may be entitled to cash compensation for having used or being exposed to some evil item or substance some time in the last few decades.  The pitch always includes a comment that there’s no cost to you unless there is a settlement in your favor.

Much of this is rubbish, but when the appeal suggests that there’s nothing to lose, why not take a shot.  And, as you would expect, “advisors” are standing by 24/7 to take your call and help get the process in motion.  What kind of advisor would be available at 3 a.m.?

One version of this approach pops up every year between October 15th and December 7th.  That’s the annual open enrollment period for Medicare.  Once this is under way, insurance companies pushing Medicare Advantage plans (a.k.a., Plan C) go all out to convince folks of the golden opportunity to get aboard with this “service.” Their pitch is all about their huge networks of physicians, the comprehensiveness of their coverage, and the cost savings these plans provide.

These plans are more appropriately called Medicare Disadvantage plans if for no other reason than the reality that the very best specialists are not included in their networks.  What’s more, you can bet that a number of the services you might otherwise expect from them would not be included.  Here’s an excellent example of the importance of reading the fine print.  It doesn’t read well here.

Let’s not overlook the bombardment of drug commercials.  Drug companies typically make huge investments in the development of new prescription drugs.  Once the drugs are approved, you can expect an onslaught of media time featuring smiling people having a good time.  You can be one of them, too, if you don’t mind ignoring the possible side effects, which are usually noted in fine print or rapid announcements.  Not infrequently, the side effects are pretty bad.

Then, too, there are commercials about pseudo drugs that have not been passed by the FDA.  One that is regularly featured claims to improve memory functions.  For these, there are usually testimonials by users (or testimonialists) who offer hedged praise about their benefits.

Caveat emptor!

 

N. Russell Wayne

Sound Asset Management Inc.

Weston, CT  06883

 

203-895-8877

www.soundasset.blogspot.com

Comments

Post a Comment

Popular posts from this blog

Sound Advice: July 16, 2025

Fixed annuities are poor investments Fixed annuities are often criticized as poor investments for several reasons, despite their reputation for providing stable, predictable income.  Here are the key drawbacks and concerns:   High Fees and Commissions Internal Fees:  Fixed annuities can carry a range of fees, including administrative charges, mortality expense risk fees, and rider fees. These can add up to 2%–4% per year, significantly eroding returns over time. Commissions:  Sales agents and financial advisors often receive high commissions for selling annuities—sometimes as much as 5%–8% of the invested amount. This creates a financial incentive for advisers to recommend them, even when they may not be the best fit for the client. Comparison to Other Investments:  Mutual funds and ETFs typically have much lower fees and commissions, making them more cost-effective for long-term growth. Limited Growth a...
Post a Comment
Read more

Sound Advice: October 8, 2025

How many investors have outperformed the stock market over the last 20 years? Very few investors have outperformed the stock market over the past 20 years.   Data shows that only about 6% to 8% of actively managed equity funds in the U.S. beat the market over this period, with the vast majority—over 90%—underperforming the S&P 500 or equivalent broad indexes. Percentage of Investors Beating the Market Only 8% of equity funds investing in large companies managed to outperform the market over a recent 20-year span. About 94% of all domestic funds underperformed the S&P 1500 Composite Index from 2005-2024. Over shorter timeframes (5-10 years), typically fewer than 15-20% of fund managers beat the S&P 500, and performance persistence is rare. Why It Is Rare The S&P 500’s high returns have proven immensely difficult to beat, especially as indexing has become popular and markets have ...
Post a Comment
Read more

Sound Advice: November 10, 2025

The stock market indexes seem to be dominated by a handful of tech stocks, but how is the average stock doing? As of late October/early November 2025, the S&P 500 index excluding the Magnificent Seven stocks (the "Other 493") has delivered a modest year-to-date return of approximately 5.3% to 5.4%. That’s barely more than one third of the performance of the full, market-capitalization-weighted S&P 500 index, which was up around 15.1% to 16% over the same period.  (The Magnificent Seven stocks are Alphabet (Google), Amazon, Apple, Meta (Facebook), Microsoft, Nvidia, and Tesla.) Index Concentration and Market Breadth The S&P 500 Equal Weight Index underperformed the standard, cap-weighted S&P 500 by about 12% in 2024, reflecting the gap between the top performing giants and the rest of the market. Only sectors like utilities, industrials, real estate, and energy outperformed their cap-weighted peers, while tech and consumer-focused sectors were ...
Post a Comment
Read more